Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

1 Views
administrator
administrator
07/16/23

Visit http://www.ecancer.org for more

Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next